Study of Immunotherapy Plus ADI-PEG 20 for the Treatment of Advanced Uveal Melanoma
Status:
Active, not recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
This study is measuring the safety of the study drug, ADI-PEG 20, combined with immunotherapy
drugs nivolumab and ipilimumab in treating patients with advanced uveal melanoma.